Vascular Aging and Acute Kidney Injury After Cardiac Surgery

July 22, 2026 updated by: Nanjing First Hospital, Nanjing Medical University

Multidimensional Assessment of Vascular Aging and Its Association With Postoperative Acute Kidney Injury in Patients Undergoing Cardiac Surgery

This prospective observational cohort study will enroll adult patients undergoing cardiac surgery at Nanjing First Hospital, Nanjing Medical University. The study will evaluate multidimensional vascular aging markers before surgery and assess their association with postoperative acute kidney injury within 7 days after surgery. No intervention will be assigned by the study protocol, and all perioperative management will follow routine clinical practice.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Acute kidney injury is a common postoperative complication after cardiac surgery and is associated with adverse short-term and long-term outcomes. Vascular aging may reflect systemic vascular dysfunction, impaired vascular compliance, endothelial dysfunction, and reduced renal perfusion reserve, which may increase susceptibility to postoperative acute kidney injury.

This prospective observational cohort study will include adult patients scheduled to undergo cardiac surgery at Nanjing First Hospital, Nanjing Medical University. Perioperative vascular aging-related indicators will be collected according to the study protocol. These indicators may include noninvasive vascular assessments, hemodynamic measurements, and relevant clinical and laboratory variables. Postoperative renal function will be monitored after surgery, and acute kidney injury will be assessed within 7 days after surgery according to predefined diagnostic criteria.

The primary objective is to investigate the association between multidimensional vascular aging markers and the occurrence and severity of postoperative acute kidney injury. Secondary analyses may evaluate the relationships between vascular aging burden and postoperative clinical outcomes, including intensive care unit stay, hospital stay, and other postoperative complications when available. This is an observational study, and no treatment, surgical procedure, or perioperative management strategy will be assigned by the study protocol.

Study Type

Observational

Enrollment (Estimated)

472

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Jiangsu
      • Nanjing, Jiangsu, China, 210006
        • Nanjing First Hospital, Nanjing Medical University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population will consist of adult patients undergoing cardiac surgery at Nanjing First Hospital, Nanjing Medical University. Eligible patients will receive perioperative vascular aging assessment and postoperative renal function monitoring according to the study protocol. Participants will be followed for postoperative acute kidney injury within 7 days after surgery.

Description

Inclusion Criteria:

  • Adult patients aged 18 years or older.
  • Patients scheduled to undergo cardiac surgery at Nanjing First Hospital, Nanjing Medical University.
  • Patients who are able to provide written informed consent.
  • Patients who are expected to undergo perioperative vascular aging assessment and postoperative renal function monitoring according to the study protocol.

Exclusion Criteria:

  • Patients younger than 18 years.
  • Patients with preoperative end-stage renal disease or maintenance dialysis.
  • Patients who are unable to complete the study-specified vascular aging assessment.
  • Patients who decline participation or withdraw informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Cardiac Surgery Cohort
Adult patients undergoing cardiac surgery at Nanjing First Hospital who will receive perioperative vascular aging assessment and postoperative renal function monitoring according to the study protocol. No treatment or perioperative management strategy will be assigned by the study protocol.
Other: Multidimensional Vascular Aging Assessment
Perioperative assessment of vascular aging-related indicators, including noninvasive vascular assessments, hemodynamic measurements, and relevant clinical and laboratory variables. The assessment is observational and will not determine the treatment, surgical procedure, or perioperative management assigned to participants.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Postoperative Acute Kidney Injury Within 7 Days After Surgery
Time Frame: From the date of surgery to postoperative day 7
Postoperative acute kidney injury will be assessed within 7 days after surgery according to predefined diagnostic criteria based on postoperative renal function changes. The outcome will be recorded as the occurrence of acute kidney injury during the postoperative 7-day period.
From the date of surgery to postoperative day 7

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Severity of Postoperative Acute Kidney Injury
Time Frame: From the date of surgery to postoperative day 7
The severity of postoperative acute kidney injury will be classified according to predefined staging criteria during the postoperative 7-day period.
From the date of surgery to postoperative day 7

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Nanjing First Hospital, Nanjing Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 1, 2026

Primary Completion (Estimated)

February 21, 2027

Study Completion (Estimated)

December 28, 2027

Study Registration Dates

First Submitted

July 22, 2026

First Submitted That Met QC Criteria

July 22, 2026

First Posted (Actual)

July 27, 2026

Study Record Updates

Last Update Posted (Actual)

July 27, 2026

Last Update Submitted That Met QC Criteria

July 22, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • KY20260625-09

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be publicly shared because the study involves clinical data from hospitalized patients and data sharing is restricted by institutional policies and participant privacy protection requirements. De-identified aggregate results may be made available in publications.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postoperative Complications

Clinical Trials on Multidimensional Vascular Aging Assessment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe